2003
DOI: 10.1073/pnas.0234057100
|View full text |Cite
|
Sign up to set email alerts
|

Gα12 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF

Abstract: Activated G␣13 stimulated the RhoGEF activity of p115 through interaction with the N-terminal RGS domain. However, G␣12 could not activate Rho through p115, although it interacted with the RGS domain of p115. The biochemical mechanism from G␣12 to Rho activation remained unknown. In this study, we analyzed the interaction of leukemia-associated RhoGEF (LARG), which also contains RGS domain, with G␣12 and G␣13. RGS domain of LARG demonstrated G␣12-and G␣13-specific GAP activity. LARG synergistically stimulated … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
236
2

Year Published

2003
2003
2020
2020

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 199 publications
(243 citation statements)
references
References 28 publications
5
236
2
Order By: Relevance
“…Activated Ga 12/13 in turn binds to and activate rhoGEFs Suzuki et al, 2003), which then activate RhoA (Dhanasekaran and Dermott, 1996;Kurose, 2003). Ga 13 has been directly implicated in GPCRstimulated cell migration (Offermanns et al, 1997;Radhika et al, 2004).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Activated Ga 12/13 in turn binds to and activate rhoGEFs Suzuki et al, 2003), which then activate RhoA (Dhanasekaran and Dermott, 1996;Kurose, 2003). Ga 13 has been directly implicated in GPCRstimulated cell migration (Offermanns et al, 1997;Radhika et al, 2004).…”
Section: Resultsmentioning
confidence: 99%
“…Transient transfection PC-3 cells were transiently transfected with mammalian expression vectors encoding FRNK, the dominant-negative mutant form of FAK (kindly provided by Dr Filippo Giancotti) or Ga 13 -CT, the dominant-negative mutant form of Ga 13 (Suzuki et al, 2003) using Lipofectamine (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommendations. Cytomegalovirus promoter driven pGFP-C1 plasmid (CLONTECH, CA, USA) was used as a transfection control to evaluate the transfection efficiency.…”
Section: Antibodies and Reagentsmentioning
confidence: 99%
“…It was recently shown that Fyn may stimulate LARG activity downstream of integrins (Guilluy et al, 2011), but we observe, rather, an inhibition of Src family kinases upon loss of CD98hc in our experimental model, which suggests that LARG has to be activated by other means. These may possibly include phosphorylation by kinases such as PKC or FAK, for instance (Chikumi et al, 2002;Disatnik et al, 2002;Suzuki et al, 2003;Dovas et al, 2006), as well as regulation of LARG homodimerization by CD98hc, which has long been known to regulate its activity (Chikumi et al, 2004). Further molecular investigations, in vitro, in cell culture should be performed to dissect this regulation.…”
Section: Discussionmentioning
confidence: 99%
“…After 4 h, FBS was supplemented into the culture to a final concentration of 10%. Cells were harvested after 20 h. Immunoprecipitation by myc antibody in the presence or absence of AlF 4 Ϫ was performed as described (14). The immunoprecipitates were loaded onto 10% SDS͞polyacrylamide gel for electrophoresis and immunoblotted with anti-myc antibody (Sigma) or anti-flag M2 antibody (Sigma).…”
Section: Methodsmentioning
confidence: 99%
“…Recently, two other mammalian RhoGEFs with the RGS domain (RGS-RhoGEFs), PSD-95͞Dlg͞ZO-1 (PDZ)-RhoGEF, and leukemia-associated RhoGEF (LARG), have been shown to mediate Rho activation through G␣12͞13 (12)(13)(14).…”
mentioning
confidence: 99%